ICON picks Microsoft to expand AI use in clinical trials
ICON plc has selected Microsoft as a preferred technology partner to advance its digital innovation and AI strategy over the next three years. The partnership involves an enterprise-wide deployment of Microsoft 365 Copilot and a cloud infrastructure to scale ICON's Orbis platform. Key focus areas include developing an intelligence layer, boosting productivity, and deploying domain-specific agents to improve clinical trial processes.
*this image is generated using AI for illustrative purposes only.
ICON plc has selected Microsoft as a preferred technology partner to advance its previously announced plan to invest in digital innovation and AI over the next three years. This strategic partnership incorporates an enterprise-wide deployment of Microsoft 365 Copilot alongside an enterprise-grade cloud, data, and AI infrastructure. The collaboration aims to further scale Orbis, ICON’s secure, governed agentic AI platform, to enhance clinical development processes.
The partnership focuses on three key areas of ICON’s AI strategy: Intelligence Layer, Productivity, and Domain-specific agents. Microsoft will support the development of a modern data layer powered by Microsoft Fabric and Azure data services to connect, harmonise, and govern ICON’s clinical, operational, and enterprise data. ICON is also expanding Microsoft 365 Copilot and Copilot Chat to every employee to automate high-volume, repeatable tasks and redirect human expertise to higher-value activities.
Through the Orbis platform, ICON is building an intelligence layer that connects expertise, data, and AI across the trial lifecycle. The platform leverages frontier model capabilities combined with ICON's operational expertise to impact the trial lifecycle significantly. Key benefits include accelerating study design using AI-enabled protocol digitisation, optimisation, and scenario modelling, as well as streamlining operational execution across various workflows.
The platform also enhances patient and site engagement by offering intelligent assistants for burden reduction, safety insights, and improved communication. Furthermore, it strengthens decision-making by enabling real-time detection of risks, trends, and operational signals. Using Microsoft Azure, Microsoft AI Services, and Microsoft Foundry, ICON will further develop and deploy agents embedded directly within clinical trial workflows securely and responsibly.
Key Strategic Focus Areas
| Focus Area | Description |
|---|---|
| Intelligence Layer | Development of a modern data layer powered by Microsoft Fabric and Azure to connect and govern data. |
| Productivity | Expansion of Microsoft 365 Copilot to all employees to automate tasks and improve efficiency. |
| Domain-specific Agents | Deployment of agents within clinical trial workflows using Microsoft Azure and AI Services. |
Impact on Clinical Trial Lifecycle
- Accelerating study design: AI-enabled protocol digitisation, optimisation, and scenario modelling.
- Streamlining operational execution: Support for workflows across feasibility, site identification, start-up, monitoring, data review, and regulatory documentation.
- Enhancing patient and site engagement: Intelligent assistants for burden reduction, safety insights, and improved communication.
- Strengthening decision-making: Real-time detection of risks, trends, and operational signals.
How will the integration of Microsoft 365 Copilot and the Orbis platform impact ICON's operational margins over the next three years?
What specific regulatory challenges might ICON face when deploying AI agents directly into clinical trial workflows?
Could this partnership set a new industry standard that pressures competitors to accelerate their own AI adoption strategies?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
